This panel is known for the detection of about 100 different autoimmune disorders that affect between 5-9% of the population at the preclinical and clinical stages of autoimmune diseases.
In autoimmune diseases, researchers have found that the pathogenic autoreactive antibodies or reactive T cells against defined self-antigens can appear in the blood years before the development of the active disease. It has been shown that autoantibodies can be present in the blood from 3 months to 19 years before the development of different autoimmune diseases.
Therefore, as indicated in the figure below, the art of preventing autoimmune diseases is early detection.
Patients in the initiation phase, even with the presence of antibodies in the blood such as Anti-Nuclear Antibody (ANA), Extractable Nuclear Antigen (ENA), Rheumatoid Factor (RF), Double-Stranded DNA (dsDNA), Actin, Mitochondrial Antibodies, and Immune Complexes are typically unaware of clinical symptoms either because their health care provider does not order any blood tests or will consider CBC, chemistry, CRP and other basic tests as sufficient. No screening for possible autoimmunity is done.
This panel, which includes ANA, ENA, RF, dsDNA, Actin, Mitochondrial Antibodies, plus Total C1Q Immune Complexes, is beneficial for a wide variety of patients with:
1. Elevation of antibodies against different viruses, including EBV, Cytomegalovirus (CMV), Herpes 1+2, Human Herpes Virus 6 (HHV-6), Varicella Zoster Virus (VZV) and Measles
2. History of exposure to toxic chemicals
3. Severe reaction to drugs
4. Immune reactivity to food, including gluten and dairy
5. One of many different autoimmune diseases
6. Neurodegenerative diseases
7. Long COVID
8. Autism spectrum
The Autoimmune Comprehensive Profile is a general screen for over 80 different autoimmune diseases that affect 7-10% of the world’s population.
.jpg)
